PI Lin-jun, MA Chun-lin, LI Hai-long, et al. Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(5): 121-125.
DOI:
PI Lin-jun, MA Chun-lin, LI Hai-long, et al. Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells[J]. Chinese journal of experimental traditional medical formulae, 2018, 24(5): 121-125. DOI: 10.13422/j.cnki.syfjx.2018050121.
Effect of Serum Containing Shenqi Yiliu Prescription on Proliferation and Cycle of Gastric Cancer BGC-823 Cells
Objective:To investigate the effect of serum containing Shenqi Yiliu prescription on inhibiting cell proliferation and blocking cell cycle of gastric cancer cell lines BGC-823
and explore its possible mechanism. Method:After being treated with 3%
5% and 10% serum containing Shenqi Yiliu prescription
gastric cancer cell lines BGC-823 were tested by 3-(4
5-dimethyl-2-thiazolyl)-2
5-diphenyl-2-H-tetrazolium bromide for proliferation; flow cytometry was used to detect the cell cycle; Real-time PCR technique was used to detect the mRNA expression of cyclin-dependent kinase inhibitor 1B (CDKN1B) and cyclin-dependent kinase inhibitor 1C (CDKN1C) genes; and Western blot was employed to test the protein expression levels of p27 and p57. Result:After 24
48
72 hours treatment with different concentrations of serum containing Shenqi Yiliu prescription
the cell viability was decreased significantly (P<0.01) in a time and dose dependent manner. Flow cytometry analysis showed
when treated by different concentrations of serum containing Shenqi Yiliu prescription for 24h
BGC-823 cells count in S phase was decreased significantly and increased in G0/G1 phase. Real-time PCR results showed
as compared with blank control group and solvent group
CDKN1B and CDKN1C mRNA expression levels were increased in each Shenqi Yiliu prescription group (P<0.05
P<0.01). Western blot results showed that as compared with blank control group
p27 and p57 protein expression levels were increased significantly in each Shenqi Yiliu prescription group (P<0.05
P<0.01). Conclusion:The serum containing Shenqi Yiliu prescription can inhibit the BGC-823 cell proliferation and the mechanism may be associated with regulating CDKN1B
CDKN1C mRNA and protein expression to intervene in the cell cycle.